A small study suggests that postmenopausal women with partners may have better quality of life than women without partners when experiencing a number of sexual side effects from hormonal therapy.
Latest MONALEESA-3 results show Kisqali and Faslodex offer better overall survival than Faslodex alone in postmenopausal women diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer that either hadn't been treated yet or had been treated with only one hormonal therapy.
A new study has found that exercise eases joint pain that's a common side effect of aromatase inhibitors.
An analysis of three studies on different CDK4/6 inhibitors in combination with an aromatase inhibitor to treat postmenopausal women diagnosed with metastatic, hormone-receptor-positive, HER2-negative breast cancer found the treatment combination was effective in both younger and older women.
Women treated for breast cancer who did more moderate-to-vigorous exercise reported fewer memory problems.
A study has found that women diagnosed with early-stage, hormone-receptor-positive breast cancer with no prescription drug coverage were less likely to start hormonal therapy than women who had insurance coverage for prescription drugs.
A study has found that Prolia improved disease-free survival for postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer taking an aromatase inhibitor.
A small study has found that a telephone counseling program helped overweight postmenopausal women diagnosed with early-stage breast cancer who were taking Femara lose weight.
Results from the MONALEESA-7 trial show that adding Kisqali to hormonal therapy and ovarian suppression significantly improves overall survival in premenopausal women diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer.
A small, early study found that a tamoxifen gel applied directly to the breast area of women diagnosed with DCIS stopped cancer cell growth as well as tamoxifen pills and caused fewer side effects.
Electroacupuncture ‚Äì a type of acupuncture where a small electric current passes between pairs of acupuncture needles ‚Äì has been found to ease fatigue, anxiety, and depression in women diagnosed with early-stage breast cancer who are taking an aromatase inhibitor.
Many young women don't think hormonal therapy is an essential treatment for breast cancer, which may be why they stop the treatment early.
The antidepressant duloxetine can ease joint pain in women diagnosed with early-stage, hormone-receptor-positive breast cancer who are taking an aromatase inhibitor.
Adding Afinitor to Faslodex offers benefits when treating metastatic, hormone-receptor-positive, HER2-negative breast cancer that has become resistant to aromatase inhibitors.
Treating premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer with tamoxifen plus 2 years of ovarian suppression after surgery offers better disease-free survival than tamoxifen alone.
Latest results from MONARCH 2 study show adding Verzenio to Faslodex improves overall survival by 9 months for advanced-stage, hormone-receptor-positive, HER2-negative breast cancer.
A study suggests that appropriate use of adjuvant hormonal therapy has improved since 2004, but still isn't optimal.
Postmenopausal women diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer with one to three positive lymph nodes and an Oncotype DX Recurrence Score of 25 or lower being treated with hormonal therapy after surgery can safely skip chemotherapy.
Experimental alpelisib combined with Faslodex improved progression-free survival more than Faslodex alone in people diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Kisqali along with either an aromatase inhibitor or tamoxifen and medicine to suppress ovarian function offers better progression-free survival than just hormonal therapy and ovarian suppression in premenopausal women with advanced-stage, hormone-receptor-positive, HER2-negative disease.
Hormonal therapy medicines used to reduce the risk of recurrence have different side effects.
Taking Arimidex for 3 years after 5 years of tamoxifen reduced the risk of the cancer coming back in women diagnosed with hormone-receptor-positive breast cancer.
Removing the ovaries and taking tamoxifen after breast cancer surgery had benefits for premenopausal women shows a new study done in Vietnam and China.
A small study shows that women who took the aromatase inhibitor Arimidex (chemical name: anastrozole) for 2 years didn't have any more thinking and memory problems than women who took a placebo pill for 2 years.